Form 4: United Therapeutics CEO Executes Pre-Arranged Stock Sales

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed planned stock option exercises and subsequent sales of common stock under a Rule 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock.
• On October 21, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
• On the same day, 3,500 shares of common stock were sold in multiple trades at weighted average prices ranging from $425.3831 to $432.2.
• On October 22, 2025, Rothblatt exercised an additional 4,000 stock options at an exercise price of $120.26 per share.
• Also on October 22, 2025, 4,000 shares of common stock were sold in multiple trades at weighted average prices ranging from $420.4701 to $423.0686.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan covers a tranche of 294,000 stock options expiring on March 15, 2026, and is set to continue until December 31, 2025, or until the options are exhausted.
• Following these transactions, Rothblatt directly holds 130 shares of common stock.
• Indirect beneficial ownership includes 166 shares by spouse and 644,193 shares across various family trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions are routine under a 10b5-1 plan, which is a standard practice. The high sale prices relative to the exercise price are positive for the individual, but the filing itself does not provide company-specific news that would significantly alter overall sentiment.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and compliant approach to insider stock sales.
• The sale prices for the common stock were significantly higher than the exercise price of the stock options, indicating a profitable transaction for the reporting person.

Negatives

• NA

Risks

• NA

Future Outlook

The pre-arranged 10b5-1 trading plan, initiated on May 2, 2025, is scheduled to continue until December 31, 2025, or until a tranche of 294,000 stock options expiring on March 15, 2026, is exhausted.

Industry Context

This filing represents a routine insider transaction under a pre-arranged trading plan, which is a common practice among executives in publicly traded companies across all industries, including biotechnology. It does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• Shares are held indirectly by spouse and in various family trusts where the reporting person and/or immediate family members are beneficiaries or have shared investment power.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-scheduled insider transactions and do not reflect a change in company fundamentals or outlook.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider trading report.

Next Steps

• Continuation of the Rule 10b5-1 trading plan until December 31, 2025, or until the specified tranche of stock options is fully exercised/sold.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation, Biotechnology